I investigate how to ethically communicate about a phase I gene transfer trial for choroideremia, a blinding retinopathy, in light of this novel biotechnology’s portrayal as a potential ‘cure’. I analyzed gene transfer communications in three contexts: (1) interviews with clinicians (n=15),...